SIDLEY AUSTIN LLP for MALLINCKRODT PHARMACEUTICALS
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Educate federal agencies and congressional offices on the continuing need for specific nuclear reactors around the world to be available for the production of supplies of a radioactive material (molybdenum-99) sufficient to manufacture the Tc-99m generator medical-imaging radiopharmaceutical product
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELIZABETH A. KOLBE New | Intern; Sen. John Kerry |
| WILLIAM A SARRAILLE New | N/A |
| ANDREW W SHOYER New | Assistent General Counsel, USTR ; ; Legal Advisor, U.S. Mission to the WTO |
Energy/Nuclear ENG
Educate federal agencies and congressional offices on the continuing need for specific nuclear reactors around the world to be available for the production of supplies of a radioactive material (molybdenum-99) sufficient to manufacture the Tc-99m generator medical-imaging radiopharmaceutical product
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELIZABETH A. KOLBE New | Intern; Sen. John Kerry |
| WILLIAM A SARRAILLE New | N/A |
| ANDREW W SHOYER New | Assistent General Counsel, USTR ; ; Legal Advisor, U.S. Mission to the WTO |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| MALLINCKRODT PLC | Ireland | Ireland | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.